p.98 抽出テキスト

110. Vigen KK, Reeder SB, Hood MN, Steckner M, Leiner T, Dombroski DA, et al. Recommendations for imaging patients with cardiac implantable electronic devices (CIEDs). J Magn Reson Imaging 2021;53:1311–1317. https://doi.org/10.1002/jmri. 27320 111. Bhuva AN, Feuchter P, Hawkins A, Cash L, Boubertakh R, Evanson J, et al. MRI for patients with cardiac implantable electronic devices: simplifying complexity with a ‘onestop’ service model. BMJ Qual Saf 2019;28:853–858. https://doi.org/10.1136/bmjqs- 2018-009079 112. Seewoster T, Lobe S, Hilbert S, Bollmann A, Sommer P, Lindemann F, et al. Cardiovascular magnetic resonance imaging in patients with cardiac implantable electronic devices: best practice and real-world experience. Europace 2019;21:1220–1228. https://doi.org/10.1093/europace/euz112 113. Stühlinger M, Burri H, Vernooy K, Garcia R, Lenarczyk R, Sultan A, et al. EHRA consensus on prevention and management of interference due to medical procedures in patients with cardiac implantable electronic devices. Europace 2022;24: 1512–1537. https://doi.org/10.1093/europace/euac040 114. Primary P, Ian Paterson D, White JA, Butler CR, Connelly KA, Guerra PG, et al. 2021 Update on safety of magnetic resonance imaging: joint statement from Canadian Cardiovascular Society/Canadian Society for Cardiovascular Magnetic Resonance/ Canadian Heart Rhythm Society. Can J Cardiol 2021;37:835–847. https://doi.org/10. 1016/j.cjca.2021.02.012 115. Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson 2017;19:75. https://doi. org/10.1186/s12968-017-0389-8 116. Baggiano A, Boldrini M, Martinez-Naharro A, Kotecha T, Petrie A, Rezk T, et al. Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 2020;13:69–80. https://doi.org/10.1016/j.jcmg.2019.03.026 117. Nordin S, Kozor R, Vijapurapu R, Augusto JB, Knott KD, Captur G, et al. Myocardial storage, inflammation, and cardiac phenotype in Fabry disease after one year of enzyme replacement therapy. Circ Cardiovasc Imaging 2019;12:e009430. https://doi.org/ 10.1161/CIRCIMAGING.119.009430 118. Ray JG, Vermeulen MJ, Bharatha A, Montanera WJ, Park AL. Association between MRI exposure during pregnancy and fetal and childhood outcomes. JAMA 2016;316: 952–961. https://doi.org/10.1001/jama.2016.12126 119. Andreini D, Dello Russo A, Pontone G, Mushtaq S, Conte E, Perchinunno M, et al. CMR for identifying the substrate of ventricular arrhythmia in patients with normal echocardiography. JACC Cardiovasc Imaging 2020;13:410–421. https://doi.org/10. 1016/j.jcmg.2019.04.023 120. Halliday BP, Baksi AJ, Gulati A, Ali A, Newsome S, Izgi C, et al. Outcome in dilated cardiomyopathy related to the extent, location, and pattern of late gadolinium enhancement. JACC Cardiovasc Imaging 2019;12:1645–1655. https://doi.org/10.1016/j.jcmg. 2018.07.015 121. Barison A, Aimo A, Ortalda A, Todiere G, Grigoratos C, Passino C, et al. Late gadolinium enhancement as a predictor of functional recovery, need for defibrillator implantation and prognosis in non-ischemic dilated cardiomyopathy. Int J Cardiol 2018; 250:195–200. https://doi.org/10.1016/j.ijcard.2017.10.043 122. Holmstrom M, Kivisto S, Helio T, Jurkko R, Kaartinen M, Antila M, et al. Late gadolinium enhanced cardiovascular magnetic resonance of lamin A/C gene mutation related dilated cardiomyopathy. J Cardiovasc Magn Reson 2011;13:30. https://doi.org/10.1186/ 1532-429X-13-30 123. Olivotto I, Maron MS, Autore C, Lesser JR, Rega L, Casolo G, et al. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2008;52:559–566. https://doi.org/10.1016/ j.jacc.2008.04.047 124. Neubauer S, Kolm P, Ho CY, Kwong RY, Desai MY, Dolman SF, et al. Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM registry. J Am Coll Cardiol 2019;74:2333–2345. https://doi.org/10.1016/j.jacc.2019.08.1057 125. Miller RJH, Heidary S, Pavlovic A, Schlachter A, Dash R, Fleischmann D, et al. Defining genotype-phenotype relationships in patients with hypertrophic cardiomyopathy using cardiovascular magnetic resonance imaging. PLoS One 2019;14:e0217612. https://doi.org/10.1371/journal.pone.0217612 126. Quarta G, Husain SI, Flett AS, Sado DM, Chao CY, Tome Esteban MT, et al. Arrhythmogenic right ventricular cardiomyopathy mimics: role of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2013;15:16. https://doi.org/10.1186/1532- 429X-15-16 127. Menghetti L, Basso C, Nava A, Angelini A, Thiene G. Spin-echo nuclear magnetic resonance for tissue characterisation in arrhythmogenic right ventricular cardiomyopathy. Heart 1996;76:467–470. https://doi.org/10.1136/hrt.76.6.467 128. Sen-Chowdhry S, Syrris P, Ward D, Asimaki A, Sevdalis E, McKenna WJ. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation 2007;115:1710–1720. https://doi.org/10.1161/CIRCULATIONAHA.106.660241 129. Aquaro GD, Barison A, Todiere G, Grigoratos C, Ait Ali L, Di Bella G, et al. Usefulness of combined functional assessment by cardiac magnetic resonance and tissue characterization versus task force criteria for diagnosis of arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol 2016;118:1730–1736. https://doi.org/10.1016/j. amjcard.2016.08.056 130. Petersen SE, Selvanayagam JB, Wiesmann F, Robson MD, Francis JM, Anderson RH, et al. Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. J Am Coll Cardiol 2005;46:101–105. https://doi.org/10.1016/j.jacc.2005. 03.045 131. Masso AH, Uribe C, Willerson JT, Cheong BY, Davis BR. Left ventricular noncompaction detected by cardiac magnetic resonance screening: a reexamination of diagnostic criteria. Tex Heart Inst J 2020;47:183–193. https://doi.org/10.14503/THIJ-19-7157 132. Grothoff M, Pachowsky M, Hoffmann J, Posch M, Klaassen S, Lehmkuhl L, et al. Value of cardiovascular MR in diagnosing left ventricular non-compaction cardiomyopathy and in discriminating between other cardiomyopathies. Eur Radiol 2012;22:2699–2709. https://doi.org/10.1007/s00330-012-2554-7 133. Jacquier A, Thuny F, Jop B, Giorgi R, Cohen F, Gaubert JY, et al. Measurement of trabeculated left ventricular mass using cardiac magnetic resonance imaging in the diagnosis of left ventricular non-compaction. Eur Heart J 2010;31:1098–1104. https://doi. org/10.1093/eurheartj/ehp595 134. Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, et al. Identification and assessment of Anderson–Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 2013;6: 392–398. https://doi.org/10.1161/CIRCIMAGING.112.000070 135. Deva DP, Hanneman K, Li Q, Ng MY, Wasim S, Morel C, et al. Cardiovascular magnetic resonance demonstration of the spectrum of morphological phenotypes and patterns of myocardial scarring in Anderson–Fabry disease. J Cardiovasc Magn Reson 2016;18: 14. https://doi.org/10.1186/s12968-016-0233-6 136. Francone M. Role of cardiac magnetic resonance in the evaluation of dilated cardiomyopathy: diagnostic contribution and prognostic significance. ISRN Radiol 2014;2014: 365404. https://doi.org/10.1155/2014/365404 137. Di Marco A, Anguera I, Schmitt M, Klem I, Neilan TG, White JA, et al. Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis. JACC Heart Fail 2017;5:28–38. https://doi.org/10.1016/j.jchf.2016.09.017 138. Klem I, Klein M, Khan M, Yang EY, Nabi F, Ivanov A, et al. Relationship of LVEF and myocardial scar to long-term mortality risk and mode of death in patients with nonischemic cardiomyopathy. Circulation 2021;143:1343–1358. https://doi.org/10.1161/ CIRCULATIONAHA.120.048477 139. Rastegar N, Te Riele ASJM, James CA, Bhonsale A, Murray B, Tichnell C, et al. Fibrofatty changes: incidence at cardiac MR imaging in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Radiology 2016;280:405–412. https://doi. org/10.1148/radiol.2016150988 140. te Riele ASJM, Bhonsale A, James CA, Rastegar N, Murray B, Burt JR, et al. Incremental value of cardiac magnetic resonance imaging in arrhythmic risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol 2013;62:1761–1769. https://doi.org/10.1016/j.jacc.2012.11. 087 141. Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 2014;130:484–495. https://doi.org/10.1161/CIRCULATIONAHA.113.007094 142. He D, Ye M, Zhang L, Jiang B. Prognostic significance of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy. Heart Lung 2018;47:122–126. https://doi.org/10.1016/j.hrtlng.2017.10.008 143. Weissler-Snir A, Dorian P, Rakowski H, Care M, Spears D. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy–are there predictors of appropriate therapy? Heart Rhythm 2021;18:63–70. https://doi.org/10.1016/j.hrthm. 2020.08.009 144. Raman B, Ariga R, Spartera M, Sivalokanathan S, Chan K, Dass S, et al. Progression of myocardial fibrosis in hypertrophic cardiomyopathy: mechanisms and clinical implications. Eur Heart J Cardiovasc Imaging 2019;20:157–167. https://doi.org/10.1093/ehjci/ jey135 145. Ho CY, Abbasi SA, Neilan TG, Shah RV, Chen Y, Heydari B, et al. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. Circ Cardiovasc Imaging 2013;6:415–422. https://doi.org/10.1161/CIRCIMAGING.112.000333 146. Moon JC, Fisher NG, McKenna WJ, Pennell DJ. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart 2004;90:645–649. https://doi.org/10.1136/hrt.2003.014969 147. Aquaro GD, De Luca A, Cappelletto C, Raimondi F, Bianco F, Botto N, et al. Prognostic value of magnetic resonance phenotype in patients with arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2020;75:2753–2765. https://doi.org/10. 1016/j.jacc.2020.04.023 Downloaded from academic.oup.com/eurheartj/article/44/37/3503/7246608 by guest on 07 October 2026